Atrium Therapeutics/$RNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atrium Therapeutics
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Ticker
$RNA
Sector
Primary listing
Employees
-
Headquarters
Website
RNA Metrics
BasicAdvanced
$205M
-
-$3.19
-
-
Price and volume
Market cap
$205M
52-week high
$16.77
52-week low
$11.95
Financial strength
Current ratio
0.068
Quick ratio
0.002
Total debt to equity
-5.855
Profitability
EBITDA (TTM)
-49.308
Gross margin (TTM)
-137.76%
Net profit margin (TTM)
-265.88%
Operating margin (TTM)
-266.58%
Effective tax rate (TTM)
0.29%
Management effectiveness
Return on assets (TTM)
-399.25%
Return on equity (TTM)
79.96%
Valuation
Price to revenue (TTM)
11.025
Price to book
-3.27
Price to tangible book (TTM)
-3.27
Price to free cash flow (TTM)
-4.821
Free cash flow yield (TTM)
-20.74%
Free cash flow per share (TTM)
-2.744
Growth
Revenue change (TTM)
70.85%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Atrium Therapeutics stock?
Atrium Therapeutics (RNA) has a market cap of $205M as of March 28, 2026.
What is the P/E ratio for Atrium Therapeutics stock?
The price to earnings (P/E) ratio for Atrium Therapeutics (RNA) stock is 0 as of March 28, 2026.
Does Atrium Therapeutics stock pay dividends?
No, Atrium Therapeutics (RNA) stock does not pay dividends to its shareholders as of March 28, 2026.
When is the next Atrium Therapeutics dividend payment date?
Atrium Therapeutics (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Atrium Therapeutics?
Atrium Therapeutics (RNA) does not currently have a Beta indicator.